OFFICIAL LEGAL TITLE
Ensuring Patient Access to Critical Breakthrough Products Act
FREQUENTLY ASKED QUESTIONS
What is the official ID of this bill?
The official print number for this legislation is 119_HR_5343.
Which chamber initiated this legislation?
This legislation was initiated in the House of Representatives.
When did the legislative process begin?
The process officially started on 2025-09-15.
What are the main provisions?
Key points include:
- Establishes a 4-year transitional coverage period for breakthrough medical devices under Medicare.
- Sets clear criteria and a process for designating devices as 'breakthrough', ensuring transparency for manufacturers and patients.
- Ensures that decisions on permanent Medicare coverage for these devices are made before the end of the transitional period, minimizing access disruptions.
- Allocates $10 million annually for fiscal years 2025-2030 to manage and implement these changes, ensuring smooth system operation.
What is the specific legal status?
The current status is Introduced.
Where can I read the full text of this legislation?
The full official text is available at:
View full text
Who is the primary sponsor?
The primary sponsor is Rep. Moore, Blake D. [R-UT-1].
What is the latest detailed status?
The latest detailed status is: Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 37 - 3.
Is this summary verified?
Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.
What is the impact of this bill?
We don't know—that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.